Tarsus Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 16, 2022, details the results of Tarsus Pharmaceuticals, Inc.'s Annual Meeting of Stockholders. The meeting was held on June 16, 2022, with a record date of April 19, 2022. At the record date, the Company had 20,727,346 shares of common stock outstanding.
Key Financial Metrics
This filing reports on corporate governance matters and does not contain financial performance data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
A quorum was established with 15,319,279 shares present. Two proposals were submitted and approved:
- Proposal 1: Election of Class II Directors. Four nominees were elected to serve until the 2025 annual meeting. All received significant majority support, with votes withheld ranging from 8,611 to 958,440. Broker non-votes totaled 4,273,814 for each nominee.
- Proposal 2: Ratification of Auditors. Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022. The vote was 15,318,215 for, 1,027 against, and 37 abstentions.
Guidance, Outlook, and Risks
This filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It is a procedural report regarding the submission of matters to a vote of security holders.
Key Facts for Investor Verification
- Verify the continued tenure of the newly elected Class II directors: Michael Ackermann, Bobak Azamian, Rosemary Crane, and Elizabeth Yeu-Lin.
- Confirm the appointment of Ernst & Young LLP as the independent auditor for the 2022 fiscal year.
- Note that the filing contains no financial results; refer to the most recent 10-K or 10-Q for financial health metrics.